Gene therapy upstart lands $45M round; Biogen picks new communications chief
→ A syndicate led by Arix Bioscience backed a big, $45 million round for LogicBio, an upstart gene therapy biotech focused on rare pediatric diseases. OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI, along with previous investor OrbiMed Israel Partners, took part in the round. The Cambridge, MA-based company uses tech developed by Adi Barzel at Tel Aviv University, Leszek Lisowski at Children’s Medical Research Institute, Australia, and Mark Kay at Stanford.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
